



## **ImmunoCellular Therapeutics' Clinical Data for ICT-107 To Be Featured at World Stem Cell Summit**

*Chief Scientific Officer to Also Discuss Research Collaborations at Prestigious Event*

LOS ANGELES (October 5, 2010) - ImmunoCellular Therapeutics (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that the company's clinical data from ICT-107 will be featured in two oral sessions at the World Stem Cell Summit, which is being held October 4-6 in Detroit, MI. John Yu, MD, ImmunoCellular's chief scientific officer and director of surgical neuro-oncology at Cedars-Sinai Medical Center in Los Angeles will present at two sessions :

- **Stem Cell Progress Report – ALS, Parkinson's and Other Neurological Diseases**  
October 5, 2010, 2:30-3:30 p.m. EST
- **Hospital Perspectives on Stem Cells and Regenerative Medicine**  
October 5, 2010, 3:30-4:30 p.m. EST

In the first session, Dr. Yu will discuss the results of a Phase I study of ICT-107, the company's lead cancer stem cell-targeting vaccine for the treatment of glioblastoma multiforme (GBM). The second session, in which Dr. Yu will also participate, will highlight the relationship between ImmunoCellular and Cedars-Sinai as an example of how industry and academia are working together to produce breakthroughs in stem cell research.

"The previously presented impressive survival and safety outcomes we have seen with ICT-107 in glioblastoma patients underscore the potential of cancer stem cell-targeting therapies to improve treatment standards for even the most aggressive of cancers," said Dr. Manish Singh, President and CEO of ImmunoCellular Therapeutics. "Industry partnerships with leading institutions such as Cedars-Sinai play a key role in our strategy to bring innovative drugs to market in the most efficient way possible. We look forward to continuing to work with Cedars-Sinai on additional studies of ICT-107 and other novel, immune-based technologies developed there, for which we have an exclusive licensing agreement."

### **About ImmunoCellular Therapeutics, Ltd.**

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently completed a Phase I trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. The Company is planning to initiate a multicenter Phase II study in late 2010. The Company's "off the shelf" therapeutic vaccine product candidate (ICT-121) targeting cancer stem cells for multiple cancer indications is targeted by IMUC to enter clinical trials during the first half of 2011. To learn more about IMUC, please visit [www.imuc.com](http://www.imuc.com)

## **About the World Stem Cell Summit**

The World Stem Cell Summit is the global stem cell and regenerative medicine community's flagship event. The Summit brings together scientists, patients, advocates, business people, investors, educators, ethicists, policy makers, and government representatives from around the world. In 2010, the Summit will attract more than 1,200 attendees from 30 nations, along with 60 exhibitors and more than 200 endorsing organizations and media partners from around the world. The 2010 World Stem Cell Summit is the largest and most comprehensive multi-track stem cell conference, featuring more than 150 international speakers and 50 hours of in-depth science, business and society presentations.

## **Forward-Looking Statements**

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including without limitation the need for substantial additional capital to fund development of product candidates beyond their initial clinical or pre-clinical stages; the risk that the safety and efficacy results obtained in the Phase I trial for ICT-107 will not be confirmed in subsequent trials; the risk that IMUC will not be able to secure a partner company for development or commercialization of ICT-107; the need to satisfy performance milestones to maintain the vaccine technology licenses with Cedars-Sinai; the risks associated with obtaining FDA clearance to commence clinical trials of the cancer stem cell vaccine on a timely basis or at all, including the need to successfully complete required animal toxicity studies; the risks associated with adhering to projected preclinical or clinical timelines and the uncertainties of outcomes of development work for product candidates, including those based on destroying cancer stem cells as a potentially safe and effective treatment for various cancers; and the risk of obtaining patent coverage for the dendritic cell-based vaccine or cancer stem cell vaccine or that any patents covering those vaccines will provide commercially significant protection for these technologies. Additional risks and uncertainties are described in IMUC's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

## **Contact Information:**

### **ImmunoCellular Therapeutics, Ltd.**

CEOcast, Inc.

Gary Nash

Investor Relations

Tel: (212) 732-4300

Email: Gnash@ceocast.com